- Title
- GOG-3119/ENGOT-en29/TROFUSE-033: A phase 3, randomised study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
- Creators
- Gemma Eminowicz - University College London Hospitals NHS Foundation TrustNicole Concin - Medical University of ViennaLynda M. Mcsorley - St. Vincent's University HospitalVojtech Tlustý - CEEGOG and Nemocnice AGEL Nový Jicín a.s, Nový Jicín, Czech RepublicFlora Zagouri - Alexandra HospitalEmad Matanes - Rambam Health Care CampusMaria Cristina Petrella - MaNGO and Oncologia Medica Ginecologica, Azienda Universitaria Ospedaliera Careggi, Firenze, ItalyElisabeth Berge Nilsen - Stavanger University HospitalKeiichi Fujiwara - Saitama Medical UniversityJian Liu Wang - Peking University People's HospitalBradley J. Monk - Gynecologic Oncology Groupet al.
- Publication Details
- International journal of gynecological cancer, Vol.36(2), p.104392
- Publisher
- Elsevier Inc
- Identifiers
- 991006256541702656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
GOG-3119/ENGOT-en29/TROFUSE-033: A phase 3, randomised study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
International journal of gynecological cancer, Vol.36(2), p.104392
02/2026
Metrics
1 Record Views